Australia Continuous Glucose Monitoring Market Size, Share - Growth Analysis Report and Forecast Trends (2026-2035)

Market Overview

The Australia continuous glucose monitoring market is shifting from a niche device for insulin-treated children to standard care. Finger-prick meters once dominated monitoring, but subsidised sensors, smartphone apps and pump integration now make continuous data the default for type 1 diabetes.

Three forces shape demand: the Australian Government subsidy, committed at AUD 682.3 million over four years; frequent product turnover as 15-day sensors replace older models; and pressure from the diabetes sector to extend funding to type 2 diabetes.

In December 2025 FreeStyle Libre 3 Plus joined the subsidy for mylife Loop users, in July 2026 FreeStyle Libre 2 left it, and from October 2026 Libre 3 Plus is available as a standalone sensor.

Key Market Trends and Insights

• Subsidy anchors demand: The Australian Government committed AUD 682.3 million over four years for subsidised CGM, and all people with type 1 diabetes can apply through the National Diabetes Services Scheme.
• Type 2 funding gap: Diabetes Australia and nine partners asked in February 2026 for subsidies covering 16,000 people with type 2 and other insulin-treated diabetes, at AUD 106.48 million over four years.
• Longer wear sensors: Abbott's FreeStyle Libre 2 Plus and 3 Plus last 15 days, against 10 days for Dexcom G7 and 7 days for the Medtronic Guardian sensor, cutting the sensors a user needs each year.
• Pump integration: The October 2026 NDSS compatibility chart lists Dexcom G7 with three pumps, Libre 3 Plus with two and Libre 2 Plus with Omnipod 5, tying sensor choice to automated insulin delivery.

Australia Continuous Glucose Monitoring Market Size and Forecast

The market is moving from a type 1 subsidy product towards a connected care platform in which sensors, apps and insulin pumps are bought and updated together. Sensors lead because every user needs a steady supply, while software and mobile apps advance fastest as phones replace dedicated readers. Fifteen-day sensors gain share quickest, and type 2 diabetes grows fastest if subsidy is extended and private purchase widens. New South Wales remains the largest state, while Western Australia grows fastest. Subsidy rules, pump integration and competition between global suppliers point to a durable, multi-year demand outlook rather than a cyclical uplift.

Key Takeaways: Australia Continuous Glucose Monitoring Market

Subsidy Design Sustains Sensor Demand

Revenue is on course to rise by about 126% across the decade, from AUD 450.00 million in 2025 to AUD 1,017.44 million in 2035 at an 8.5% CAGR. Sensors are replaced every 7 to 15 days, so each subsidised registrant generates recurring demand, while the AUD 682.3 million commitment underwrites it.

Apps, Longer Wear and Type 2 Access Lead Growth

Sensors hold the largest revenue share, but software and mobile apps grow at an estimated 11.0% CAGR, 15-day sensors at 10.2% and type 2 diabetes at 12.0% through 2035. A Medical Services Advisory Committee consultation on type 2 funding closed on 12 June 2026, keeping the expansion case open.

FreeStyle Libre 3 Plus Becomes a Standalone Subsidised Sensor

Abbott's FreeStyle Libre 3 Plus moved from mylife Loop use only to standalone subsidy on 1 October 2026, widening choice for all Australians with type 1 diabetes. It needs the new Libre app, which is still coming to Australia.

• NDSS code 996, with up to six sensors per order
• Co-payment of AUD 17.90 per sensor where applicable
• Fifteen-day wear with minute-by-minute readings and no calibration

Australia Continuous Glucose Monitoring Market Report Summary

Key Insight

Subsidised access, frequent sensor replacement and pump integration make this a structural category. Sensors lead, while software, longer-wear sensors and type 2 diabetes grow fastest across the forecast period.

Key Trends in the Australia Continuous Glucose Monitoring Market

The Australia continuous glucose monitoring market is being shaped by subsidy product changes, unresolved type 2 funding, sector budget requests and the shift to longer-wear sensors.

October 2026 - FreeStyle Libre 3 Plus Becomes Available as a Standalone NDSS Sensor

• From 1 October 2026 the National Diabetes Services Scheme subsidises Abbott's FreeStyle Libre 3 Plus without an automated insulin delivery system, for Australians with type 1 diabetes.
• The 15-day sensor needs the new Libre app, which Diabetes WA says is coming soon, and cannot be bought directly from Abbott.
• Standalone access gives subsidised users a coin-sized, longer-wear alternative to Dexcom G7 and the Libre 2 Plus.

July 2026 - FreeStyle Libre 2 Sensor Delisted From the NDSS

• The NDSS removed the FreeStyle Libre 2 sensor on 1 July 2026 after Abbott Diabetes Care discontinued it.
• Users moved automatically to the FreeStyle Libre 2 Plus, a 15-day sensor with a co-payment of AUD 17.90.
• Automatic switching lifts the share of 15-day sensors without any new certification by health professionals.

May 2026 - Government Notes Recommendation to Widen CGM Access

• The government response to the parliamentary diabetes inquiry, reported on 26 May 2026, marked the CGM expansion recommendation as noted, not supported.
• That recommendation covered removing access limits and extending subsidy to gestational, type 3c and insulin-treated type 2 diabetes.
• The government said it would consider the report when deciding any future expansion of the funded program.

February 2026 - Diabetes Sector Seeks Type 2 CGM Funding in Budget Submission

• Diabetes Australia and nine partners submitted a request on 24 February 2026 for the 2026-27 Federal Budget.
• The CGM request would cover 16,000 people with type 2 and other insulin-treated diabetes at AUD 106.48 million over four years.
• It projects a net benefit of AUD 1.3 billion by 2066, or AUD 2.69 for each dollar invested.

Key Insight

Policy still defines the market. Listings change quickly and wider type 2 funding remains open, so suppliers plan for both subsidised growth and a stronger private-pay segment.

Recent Market Developments in the Australia Continuous Glucose Monitoring Market

Recent developments, presented from the most recent, show the Australia continuous glucose monitoring market moving from supplier results and listings into product launches and ownership change.

September 2026 - Medtronic Ends Standalone Guardian System (4) Transmitter Support

• From 1 September 2026 the NDSS discontinued the Guardian System (4) transmitter, code 985, for standalone use with the Guardian app.
• The transmitter stays available for people using the MiniMed 780G insulin pump with Guardian Link (4).
• Medtronic is therefore concentrating Australian sensor demand inside its pump system rather than standalone monitoring.

August 2026 - Melbourne Hosts Diabetes Congress as SIBIONICS Shows GS3

• The IDF Western Pacific Region Congress ran from 18 to 21 August 2026 in Melbourne, with about 3,000 delegates expected.
• SIBIONICS showcased its 14-day GS3 sensor at the event, though its release did not state Australian availability or approval.
• Sessions on sensors and pumps gave Australian clinicians a view of tools beyond the current subsidised range.

July 2026 - Dexcom and Abbott Report Rising Sensor Sales

• Dexcom reported second-quarter 2026 revenue of USD 1.31 billion on 30 July 2026, with international sales up 19%.
• Abbott reported Diabetes Care sales of USD 2.19 billion on 16 July 2026, with continuous glucose monitor sales up 11.0%.
• Both suppliers supply the Australian subsidy, so global growth supports investment in local support and product updates.

March 2026 - MiniMed Lists on Nasdaq After Medtronic Separation

• Medtronic's diabetes unit began trading as MiniMed on 6 March 2026, pricing 28 million shares at USD 20 each.
• The offering raised USD 560 million gross and left Medtronic with about 90% of the shares.
• The MiniMed 780G remains the Australian pump paired with the Guardian Link (4) sensor.

Key Insight

Recent activity shows suppliers reshaping portfolios around pumps and longer-wear sensors. Listings, delistings and corporate separation matter more locally than any single launch across the forecast period.

Australia Continuous Glucose Monitoring Industry Segmentation

The Expert Market Research’s report on the Australia Continuous Glucose Monitoring Market offers a detailed analysis of the market based on the following segments.

Market Breakup by Component

• Sensors
• Transmitters
• Receivers and Readers
• Software and Mobile Apps
• Others

Sensors lead because each user consumes a steady stream of disposable units, and Dexcom G7 sensors were subsidised from 1 March 2025 at an AUD 11.60 co-payment. Software and Mobile Apps grows fastest at an estimated 11.0% CAGR through 2035, as the Libre 3 Plus relies on a new app that is coming soon to Australia. Transmitters decline in relevance as the Guardian System (4) transmitter lost standalone support on 1 September 2026. Receivers and Readers remain relevant, since NDSS registrants can obtain a FreeStyle Libre 2 Reader free of charge. Others include adhesive patches, applicators and warranty replacements.

Market Breakup by Sensor Wear Duration

• Up to 7 Days
• 10 Days
• 15 Days
• Others

Ten Days leads on an estimated basis, as Dexcom G7 gained NDSS subsidy in March 2025 and remains compatible with Tandem, Omnipod 5 and mylife Ypsopump systems. Fifteen Days grows fastest at an estimated 10.2% CAGR through 2035, since FreeStyle Libre 2 Plus joined the NDSS in April 2025 and automatically replaced the Libre 2 in July 2026. Up to 7 Days covers the Medtronic Guardian sensor, now confined to the MiniMed 780G. Others include 14-day sensors, such as the SIBIONICS GS3 shown in Melbourne in August 2026, and professional sensors worn for clinical studies.

Market Breakup by Diabetes Type

• Type 1 Diabetes
• Type 2 Diabetes
• Gestational Diabetes
• Other Insulin-Requiring Diabetes
• Others

Type 1 Diabetes leads because every person with the condition can apply for subsidy, and Breakthrough T1D reports that over 70% already use a sensor. Type 2 Diabetes grows fastest at an estimated 12.0% CAGR through 2035, as the Medical Services Advisory Committee consultation on application 1786 closed in June 2026 and the sector seeks AUD 106.48 million for 16,000 people. Gestational Diabetes and Other Insulin-Requiring Diabetes sit within the same funding case, and the committee has called these populations small but high need. Others include prediabetes, wellness users and research cohorts.

Market Breakup by Region

• New South Wales
• Victoria
• Queensland
• Western Australia
• South Australia
• Others

New South Wales dominates with 8.67 million residents in March 2026, and it grows at an estimated 8.1% CAGR through 2035. Western Australia is fastest at an estimated 9.4%, as its population grew 2.1% in the year to March 2026 and Diabetes WA opened Libre 3 Plus clinic support from 1 October 2026. Victoria, at an estimated 8.7%, hosted the diabetes congress in August 2026 with 7.15 million residents. Queensland grows at 8.9% on 5.74 million residents, and South Australia at 7.8% on 1.92 million. Others covers Tasmania, the ACT and the Northern Territory, growing at an estimated 8.0%.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Competitive Landscape in the Australia Continuous Glucose Monitoring Market

Competition combines global sensor makers, pump partners and a few new entrants. Barriers include TGA inclusion, NDSS listing, pump and app compatibility, clinician training through credentialled educators, and the supply logistics that keep subsidised sensors available through community pharmacies.

Dexcom

Dexcom, founded in 1999 and based in San Diego, makes the G7 sensor, which has been subsidised on the NDSS since 1 March 2025 and works with Tandem, Omnipod 5 and mylife Ypsopump systems. Its Australian arm, AMSL Diabetes, supplies local customers. In July 2026 Dexcom reported second-quarter revenue of USD 1.31 billion, with international sales up 19%, and said Health Canada had cleared its 15-day G7 sensor.

Abbott

Abbott Diabetes Care, part of Abbott, makes FreeStyle Libre sensors and is the only supplier with two 15-day sensors on the NDSS. Libre 2 Plus joined on 1 April 2025, Libre 3 Plus on 1 December 2025 for mylife Loop users, and Libre 2 was delisted on 1 July 2026. Standalone Libre 3 Plus access began on 1 October 2026, and Abbott reported Diabetes Care sales of USD 2.19 billion in July 2026.

Medtronic

Medtronic Australasia sponsors the Simplera sensor on the Australian register, with Therapeutic Goods Administration advertising approvals dated February and May 2025. Its diabetes unit began trading as MiniMed on Nasdaq on 6 March 2026, raising USD 560 million gross. The NDSS ended standalone Guardian System (4) transmitter support on 1 September 2026, leaving the sensor tied to the MiniMed 780G pump.

Insulet

Insulet makes the tubeless Omnipod 5 system, launched commercially in Australia on 18 March 2025 with Dexcom G6 and G7 compatibility. Its Australian pods now pair with FreeStyle Libre 2 Plus as well as Dexcom G6, and the October 2026 NDSS chart lists Omnipod 5 as compatible with G7, Libre 2 Plus and Libre 3 Plus. Insulet is not a sensor maker, but it shapes which sensors subsidised pump users choose.

Other players operating in the Australia continuous glucose monitoring market include Ypsomed Australia, Tandem Diabetes Care, Roche Diabetes Care Australia, Revelare DX, and SIBIONICS, alongside pharmacies serving as NDSS access points, diabetes educators and app developers supporting sensor distribution and training across Australia.

Key Insight

Competition rests on subsidy listing, pump compatibility, wear time and app quality rather than price alone. Global sensor makers anchor supply, while pump partners and entrants shape patient choice.